Investors

Investors image

News

Sep.27, 2023 Release
Zatolmilast, an Investigational Treatment for Fragile X Syndrome, Receives Rare Pediatric Disease Designation from the U.S. FDA
Sep.21, 2023 Notice
Transcript of the ESWI 2023 follow-up meeting
Sep.21, 2023 Release
Regarding the Adoption of Public Offering for “the Project that Establish Biopharmaceutical Manufacturing Bases to Strengthen Vaccine Production Structure” Led by the Ministry of Economy, Trade and Industry
- Establishing domestic vaccine manufacturing for future pandemics -
Sep.19, 2023 Notice
Presentation Material of ESWI 2023 Follow Up Meeting
Sep.19, 2023 Release
Shionogi Presents New Ensitrelvir Clinical and Real-World Data Reinforcing Potential Across COVID-19 Populations at ESWI 2023
  • Latest IR Information

    ・Financial Results / Supplement

    　- Presentation material

    　- Transcript

    more
  • IR Library

    ・Financial Results / Supplement

    ・Presentation materials

    ・Annual Report / Integrated Report / EHS Report

    ・Corporate Governance Report

    ・Pipeline

    ・Fact Book

    more
  • Management Policy

    ・Philosophy

    ・Business Plan

    ・Corporate Governance

    ・Disclosure Policy

    ・Business Risks

    more
  • Shareholder Information

    ・Information on Shares

    ・General Meeting of Shareholders

    ・Analyst Coverage

    ・Bonds & Ratings

    more
  • Individual Investors

    ・Pharmaceutical Business

    ・Shionogi's Strength

    ・Business Strategy

    ・Business Activities, etc.

     

    more
  • Sustainability

    View the Shionogi's approach to sustainable growth

    more
  • Financial Highlights

    Financial highlights for the last five years

    more
  • IR Calendar

    The schedule and results of IR events in each fiscal year

     

    more